Skip to main content
Clinical Trials/NCT00537446
NCT00537446TerminatedNot Applicable

Effect of Noninvasive Positive Pressure Ventilation on Pulmonary Function Testing in Amyotrophic Lateral Sclerosis

Columbia University1 site in 1 country8 target enrollmentStarted: September 1, 2007Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
8
Locations
1
Primary Endpoint
Difference in Pulmonary Function and Respiratory Muscle Pressure Testing

Study Overview

Brief Summary

Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing failure. This breathing insufficiency is commonly treated with a breathing assistance device, known as noninvasive positive pressure ventilation (NIPPV). While generally well tolerated and accepted, it is not clear whether or to what extent NIPPV in fact helps breathing function: some data suggest that NIPPV preserves breathing function over time, whereas other data suggest that it actually causes breathing function to decline more quickly. No studies have shown what the acute effect of NIPPV is on breathing muscle function in ALS patients.

This study will test the hypothesis that the acute use of NIPPV, at pressure levels that are in common clinical use, will cause measurable changes in tests of breathing function, compared to baseline and to lower levels of NIPPV. We expect that the results of this study will help to clarify whether and to what extent NIPPV assists respiratory muscle function in patients with ALS.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Supportive Care
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •clinical diagnosis of amyotrophic lateral sclerosis
  • •clinical indication to start noninvasive ventilation (forced vital capacity < 50% predicted or signs/symptoms of respiratory insufficiency)
  • •age 18 to 80 years old

Exclusion Criteria

  • •prior institution of NIPPV
  • •inability to safely use NIPPV
  • •indications for tracheostomy assisted ventilation because of inability to clear secretions from the airway
  • •inability or unwillingness to perform pulmonary function testing
  • •presence of advanced dementia.

Arms & Interventions

High-level ventilation

Active Comparator

Each subject will spend 2 hours receiving high-level noninvasive ventilation.

Intervention: noninvasive positive pressure ventilation (Device)

Low-level ventilation

Active Comparator

Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.

Intervention: noninvasive positive pressure ventilation (Device)

Outcomes

Primary Outcomes

Difference in Pulmonary Function and Respiratory Muscle Pressure Testing

Time Frame: 5 hours

Difference in Subjective Dyspnea Between Baseline and the Two Different Ventilator Modes

Time Frame: 5 hours

Difference in Gas Exchange

Time Frame: 5 hours

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Robert C. Basner

Special Lecturer in Medicine

Columbia University

Study Sites (1)

Loading locations...

Similar Trials